AGREEMENT AND PLAN OF MERGER BY AND AMONG LOGICBIO THERAPEUTICS, INC. ALEXION PHARMACEUTICALS, INC. AND CAMELOT MERGER SUB, INC. Dated as of October 3, 2022Merger Agreement • October 3rd, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER, dated as of October 3, 2022 (this “Agreement”), is entered into by and among LogicBio Therapeutics, Inc., a Delaware corporation (the “Company”), Alexion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Camelot Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub” and, collectively with the Company and Parent, the “Parties”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 3rd, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This TENDER AND SUPPORT AGREEMENT, dated as of October 3, 2022 (this “Agreement”), is between Alexion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Camelot Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and each of the undersigned stockholders of LogicBio Therapeutics, Inc., a Delaware corporation (the “Company”) set forth on Schedule I attached hereto (each a, “Stockholder” and together, the “Stockholders”).
